Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801570 | 0.94 | KDM4E (0.45) | POLBNPC1TSHRSMN1; SMN2KDM4E | |
| SCHEMBL13957871 | 0.87 | POLB (0.44) | POLBNPC1TSHRKDM4ESYK | |
| SCHEMBL17075646 | 0.87 | KDM4E (0.48) | POLBNPC1TSHRKDM4ESYK | |
| SCHEMBL722986 | 0.87 | SYK (0.50) | POLBNPC1TSHRKDM4ESYK | |
| SCHEMBL14758443 | 0.87 | TSHR (0.62) | POLBNPC1TSHRKDM4EALDH1A1 | |
| SCHEMBL430271 | 0.84 | ALDH1A1 (0.43) | POLBNPC1TSHRSYKALDH1A1 | |
| SCHEMBL22636056 | 0.83 | ALDH1A1 (0.44) | POLBNPC1TSHRSYKALDH1A1 | |
| SCHEMBL2797649 | 0.82 | TSHR (0.52) | TSHRSMN1; SMN2KDM4ESYKALDH1A1 | |
| SCHEMBL171775 | 0.82 | ALDH1A1 (0.55) | NPC1TSHRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28502391 | 0.81 | FGFR3 (0.43) | POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | POLB 3879/4885NPC1 2455/4885TSHR 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.